Today's presentation said the data showed that plasma levels of intact parathyroid hormone (iPTH) continued to fall as serum levels of 25-hydroxyvitamin D (25D) rose above 30 ng/mL, a level considered sufficient for CKD patients in published clinical practice guidelines. These data suggest that patients with stage 3 or 4 CKD require higher levels of serum 25D than previously thought in order to control elevated iPTH.
It seems to me that this is important to Opko because Rayaldee raises this serum level. I didn't see any commentary on this presentation. I hope this isn't a step backwards in the upcoming product launch, but it seems to me that this is another indication of how much the new Rayaldee is needed.